Improvement of DSS-induced colitis by EP4 agonist administration required EPRAP, whereas cAMP, a downstream mediator of EP4, did not appear to contribute to the anti-inflammatory effect of EPRAP in the colon. Here, PTGER4 is linked to colitis.